Mode
Text Size
Log in / Sign up

Narrative review discusses MS continuum concepts for high-risk individualsNew review suggests viewing MS as a continuum helps monitor those at higher risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider conceptualizing MS as a continuum for risk stratification in high-risk individuals.

This narrative review focuses on multiple sclerosis within the context of individuals at higher risk for the disease. The publication does not report a specific sample size or setting for the evidence synthesized. The authors explore the concept of MS as a continuum to potentially improve risk stratification and monitoring strategies for this population.

The review highlights a critical gap in current knowledge. Specifically, there is an absence of biomarkers with sufficient specificity to reliably characterize preclinical or prodromal biological disease activity. Furthermore, the authors note the absence of validated tools to translate such findings into clinical practice.

Despite these limitations, the conceptual framework presented may offer a pathway for future targeted monitoring. The practice relevance lies in how viewing MS as a continuum could shape future strategies for high-risk individuals. No specific adverse events or safety data were reported in this narrative synthesis.

Multiple sclerosis is a serious condition that affects the nervous system. For years, doctors have struggled to understand exactly when the disease starts or how to catch it early. A new narrative review offers a fresh perspective. It proposes that multiple sclerosis should be seen as a continuum rather than a sudden event. This shift in thinking could change how doctors manage care for individuals at higher risk for the disease.

The authors argue that this new way of thinking might lead to better risk stratification. They hope it will also help develop targeted monitoring strategies. These strategies could catch the disease earlier or manage it more effectively before symptoms become severe. The goal is to improve outcomes for patients who are currently waiting for a clear diagnosis.

However, the review notes some important gaps in current knowledge. There are no biomarkers with enough specificity to reliably track preclinical or prodromal biological disease activity. Additionally, there are no validated tools to translate these findings into clinical practice right now. Without these tools, the new conceptual framework remains a guide for future research rather than an immediate change in daily care.

What this means for you:
Viewing MS as a continuum may help monitor those at higher risk for the disease.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Multiple sclerosis (MS) has traditionally been diagnosed after the onset of clinical symptoms, supported by characteristic radiological findings. However, mounting evidence suggests that MS-related biological processes may precede the first overt neurological manifestations by several years. The disease appears to unfold along a biological continuum that includes genetic susceptibility, environmental exposures, and possible early manifestations characterized by subtle, nonspecific symptoms that precede detectable abnormalities such as MRI lesions or early biomarker changes. This review summarizes current knowledge about the temporal evolution of MS, from early risk factors through the radiologically isolated syndrome (RIS) and clinically isolated syndrome (CIS), to the onset of clinically definite MS. We discuss emerging biomarkers, advances in neuroimaging, and evolving insights into early immunopathological mechanisms. Conceptualizing MS as a continuum may facilitate improved risk stratification and the development of targeted monitoring strategies in individuals at higher risk. Nevertheless, this model remains limited by the absence of biomarkers with sufficient specificity to reliably characterize preclinical or prodromal biological disease activity, and of validated tools to translate such findings into clinical practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.